Outpatient SUI treatment approved for marketing

Article

The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy.

The FDA has approved for marketing Novasys Medical's Renessa System, a treatment for stress urinary incontinence due to hypermobility in women unresponsive to conservative care who are not candidates for surgical therapy. The 20-minute outpatient treatment involves applying controlled heat to tissue in the lower urinary tract, denaturing collagen at multiple small sites to increase tissue resistance to involuntary leakage during increased intra-abdominal pressure.

A multicenter clinical trial in 170 women who underwent the Renessa treatment resulted in reduced incontinence episodes, pad use, and leak severity for the majority of study participants, Novasys said.

For more information, visit www.novasysmedical.com.

Related Videos
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
John Michael DiBianco, MD, answers a question during a Zoom video interview
Shaya Taghechian, MD, answers a question during a video interview
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
A panel of 4 experts on prostate cancer
Joseph Song, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.